Epitope-resolved serology test differentiates the clinical outcome of COVID-19 and identifies defects in antibody response in SARS-CoV-2 variants
Authors:
Preprint
Abstract
BACKGROUND The role of humoral immunity in the coronavirus disease 2019 (COVID-19) is not fully understood owing, in large part, to the complexity of antibodies produced in response to the SARS-CoV-2 infection. There is a pressing need for serology tests to assess patient-specific antibody response and predict clinical outcome. METHODS Using SARS-CoV-2 proteome and peptide microarrays, we screened 146 COVID-19 patients plasma samples to identify antigens and epitopes. This enabled us to develop a master epitope array and an epitope-specific agglutination assay to gauge antibody responses systematically and with high resolution. RESULTS We identified 54 linear epitopes from the Spike (S) and Nucleocapsid (N) protein and showed that epitopes enabled higher resolution antibody profiling than protein antigens. Specifically, we found that antibody responses to the S(811-825), S(881-895) and N(156-170) epitopes negatively or positively correlated with clinical severity or patient survival. Moreover, we found that the P681H and S235F mutations associated with the coronavirus variant B.1.1.7 altered the specificity of the corresponding epitopes. CONCLUSIONS Epitope-resolved antibody testing not only offers a high-resolution alternative to conventional immunoassays to delineate the complex humoral immunity to SARS-CoV-2 and differentiate between neutralizing and non-neutralizing antibodies, it may also be used as predictor of clinical outcome. The epitope peptides can be readily modified to detect antibodies against variants in both the peptide array and latex agglutination formats. FUNDING Ontario Research Fund (ORF)-COVID-19 Rapid Research Fund, the Toronto COVID-19 Action Fund, Western University, the Lawson Health Research Institute, the London Health Sciences Foundation, and the AMOSO Innovation Fund.Keywords
All Related Versions
- Published version: JCI Insight, 6 (13).
This publication has 32 references indexed in Scilit:
- Serology testing in the COVID-19 pandemic responseThe Lancet Infectious Diseases, 2020
- Natural History of Asymptomatic SARS-CoV-2 InfectionNew England Journal of Medicine, 2020
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesCell, 2020
- Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patientsJournal of Infection, 2020
- Asymptomatic SARS-CoV-2 infection: the tip or the iceberg?Thorax, 2020
- A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2Cell Host & Microbe, 2020
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosisJournal of Medical Virology, 2020
- Epitopes for a 2019-nCoV vaccineCellular & Molecular Immunology, 2020
- NIH Image to ImageJ: 25 years of image analysisNature Methods, 2012
- Whole-Blood Agglutination Assay for On-Site Detection of Human Immunodeficiency Virus InfectionJournal of Clinical Microbiology, 2003